Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1973 Sep;4(3):306–308. doi: 10.1128/aac.4.3.306

Chemotherapeutic Activity of 5-Fluorocytosine and Amphotericin B Against Candida albicans in Mice

E Titsworth 1, E Grunberg 1
PMCID: PMC444547  PMID: 4586144

Abstract

The effect of treatment with combinations of the two antifungal agents, 5-fluorocytosine (5-FC) and amphotericin B (AB), against systemic Candida albicans infections in mice was investigated. Graded doses of the single substances and of combinations of the drugs were administered daily for 21 days. The 50% curative dose (CD50) values were calculated on the basis of the presence or absence of C. albicans in cultures prepared from the kidneys of animals that succumbed during the experimental period or were sacrificed at the termination of the experiments. Overall, when graded doses of AB were administered in the presence of a constant, inactive dose of 5-FC (approximately one-half to one-fourth the CD50 of 5-FC), the CD50 values for AB were lower than those for amphotericin B alone. Similarly, the CD50s for 5-FC were reduced when AB was administered at a constant dose equal to one-half to one-fourth the CD50 of AB alone. In no instance was there evidence of antagonism.

Full text

PDF
306

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Block E. R., Bennett J. E. Pharmacological studies with 5-fluorocytosine. Antimicrob Agents Chemother. 1972 Jun;1(6):476–482. doi: 10.1128/aac.1.6.476. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Fass R. J., Perkins R. L. 5-fluorocytosine in the treatment of cryptococcal and candida mycoses. Ann Intern Med. 1971 Apr;74(4):535–539. doi: 10.7326/0003-4819-74-4-535. [DOI] [PubMed] [Google Scholar]
  3. Grunberg E., DeLorenzo W. F. Potentiation of sulfonamides and antibiotics by trimethoprim [2,4-diamino-5-(3,4,5-trimethoxybenzyl) pyrimidine]. Antimicrob Agents Chemother (Bethesda) 1966;6:430–433. [PubMed] [Google Scholar]
  4. Jawetz E. Combined antibiotic action: some definitions and correlations between laboratory and clinical results. Antimicrob Agents Chemother (Bethesda) 1967;7:203–209. doi: 10.1128/AAC.7.2.203. [DOI] [PubMed] [Google Scholar]
  5. McCabe W. R. Clinical use of combinations of antimicrobial agents. Antimicrob Agents Chemother (Bethesda) 1967;7:225–233. [PubMed] [Google Scholar]
  6. Medoff G., Comfort M., Kobayashi G. S. Synergistic action of amphotericin B and 5-fluorocytosine against yeast-like organisms. Proc Soc Exp Biol Med. 1971 Nov;138(2):571–574. doi: 10.3181/00379727-138-35943. [DOI] [PubMed] [Google Scholar]
  7. Medoff G., Kobayashi G. S., Kwan C. N., Schlessinger D., Venkov P. Potentiation of rifampicin and 5-fluorocytosine as antifungal antibiotics by amphotericin B (yeast-membrane permeability-ribosomal RNA-eukaryotic cell-synergism). Proc Natl Acad Sci U S A. 1972 Jan;69(1):196–199. doi: 10.1073/pnas.69.1.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Miller R. P., Bates J. H. Amphotericin B toxicity. A follow-up report of 53 patients. Ann Intern Med. 1969 Dec;71(6):1089–1095. doi: 10.7326/0003-4819-71-6-1089. [DOI] [PubMed] [Google Scholar]
  9. Pankey G. A., Lockwood W. R., Montalvo J. M. 5-fluorocytosine: a replacement for amphotericin B in the treatment of candida and cryptococcus neoformans infections? J La State Med Soc. 1970 Dec;122(12):365–369. [PubMed] [Google Scholar]
  10. Record C. O., Skinner J. M., Sleight P., Speller D. C. Candida endocarditis treated with 5-fluorocytosine. Br Med J. 1971 Jan 30;1(5743):262–264. doi: 10.1136/bmj.1.5743.262. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Steer P. L., Marks M. I., Klite P. D., Eickhoff T. C. 5-fluorocytosine: an oral antifungal compound. A report on clinical and laboratory experience. Ann Intern Med. 1972 Jan;76(1):15–22. doi: 10.7326/0003-4819-76-1-15. [DOI] [PubMed] [Google Scholar]
  12. Tassel D., Madoff M. A. Treatment of Candida sepsis and Cryptococcus meningitis with 5-fluorocytosine. A new antifungal agent. JAMA. 1968 Oct 21;206(4):830–832. [PubMed] [Google Scholar]
  13. Utz J. P., Tynes B. S., Shadomy H. J., Duma R. J., Kannan M. M., Mason K. N. 5-Fluorocytosine in human cryptococcosis. Antimicrob Agents Chemother (Bethesda) 1968;8:344–346. doi: 10.1128/AAC.8.3.344. [DOI] [PubMed] [Google Scholar]
  14. Vandevelde A. G., Mauceri A. A., Johnson J. E., 3rd 5-fluorocytosine in the treatment of mycotic infections. Ann Intern Med. 1972 Jul;77(1):43–51. doi: 10.7326/0003-4819-77-1-43. [DOI] [PubMed] [Google Scholar]
  15. Warner J. F., McGehee R. F., Duma R. J., Shadomy S., Utz J. P. 5-fluorocytosine in human candidiasis. Antimicrob Agents Chemother (Bethesda) 1970;10:473–475. [PubMed] [Google Scholar]
  16. Watkins J. S., Campbell M. J., Gardner-Medwin D., Ingham H. R., Murray I. G. Two cases of cryptococcal meningitis, one treated with 5-fluorocytosine. Br Med J. 1969 Jul 5;3(5661):29–31. doi: 10.1136/bmj.3.5661.29. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Zimmermann R. A., Moellering R. C., Jr, Weinberg A. N. Mechanism of resistance to antibiotic synergism in enterococci. J Bacteriol. 1971 Mar;105(3):873–879. doi: 10.1128/jb.105.3.873-879.1971. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES